Sunday, 22 July 2018 - 13:46
  • it
  • de
  • en
  • fr

Vertex Pharmaceuticals

An analysis of the potential Gilead – Vertex merger

Investors have long hoped that Gilead carries out a major acquisition, allowing the California-based biotech group to create a shift portfolio to offset the steady loss in revenue and profit due to the sharp sales decline in its hepatitis-C business….

The incredible growth of biotech industry

The American Society of Clinical Oncology Annual Meeting ended few days ago without producing any sharp rise in shares, except for Loxo Oncology, which presented data causing shares to soar by 40%. The financial community was relieved that no untoward…

2016 results from seven companies expected next week

BioPharmaDive has provided an interesting report of what we can expect from the pharma and biotech companies which will report their results next week. Such remarks are significant, especially following declarations by the US President-elect. As for Johnson & Johnson,…